Targretin
Lymphoma, T-Cell, Cutaneous, Therapeutic procedure, Disease
Treatment
4 FDA approvals
0 Active Studies for Targretin
Treatment for
Lymphoma, T-Cell, Cutaneous
What is Targretin
Bexarotene
The Generic name of this drug
Treatment Summary
Bexarotene (Targretin) is a medication approved by the FDA to treat a type of skin cancer called Cutaneous T cell lymphoma. It has also been used to treat other types of cancer, including lung cancer, breast cancer, and Kaposi's sarcoma, even though these uses are not yet approved by the FDA.
Targretin
is the brand name
Targretin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Targretin
Bexarotene
1999
17
Approved as Treatment by the FDA
Bexarotene, also called Targretin, is approved by the FDA for 4 uses which include refractory peripheral cutaneous T-cell lymphoma and Lymphoma, T-Cell, Cutaneous .
refractory peripheral cutaneous T-cell lymphoma
Lymphoma, T-Cell, Cutaneous
Therapeutic procedure
Disease
Effectiveness
How Targretin Affects Patients
Bexarotene is a type of retinoid that binds to and activates certain receptors in the body (RXR<sub>α</sub>, RXR<sub>β</sub>, and RXR<sub>γ</sub>). These receptors help regulate the growth and division of cells. Bexarotene is used to treat cutaneous T-cell lymphoma in patients who have not responded to other treatments. In laboratory and animal tests, it has been found to slow down or stop the growth of some types of cancer cells.
How Targretin works in the body
Bexarotene attaches to three specific proteins in the body, called retinoid X receptor subtypes. It is not clear how exactly bexarotene works to treat CTCL, but it has been found to be effective in all stages of the disease.
When to interrupt dosage
The measure of Targretin is contingent upon the diagnosed illness, including Lymphoma, T-Cell, Cutaneous, Therapeutic intervention and lack of success of at least one past systemic therapy. The magnitude of dosage depends on the approach of administration (e.g. Oral or Capsule, liquid filled - Oral) mentioned in the table beneath.
Condition
Dosage
Administration
Therapeutic procedure
, 75.0 mg, 0.01 mg/mg
, Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule - Oral, Topical, Gel, Gel - Topical
Disease
, 75.0 mg, 0.01 mg/mg
, Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule - Oral, Topical, Gel, Gel - Topical
Lymphoma, T-Cell, Cutaneous
, 75.0 mg, 0.01 mg/mg
, Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule - Oral, Topical, Gel, Gel - Topical
Warnings
There are 20 known major drug interactions with Targretin.
Common Targretin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Bexarotene is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Bexarotene is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Bexarotene.
Abetimus
Major
The risk or severity of adverse effects can be increased when Bexarotene is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Bexarotene.
Targretin Novel Uses: Which Conditions Have a Clinical Trial Featuring Targretin?
Currently, there are zero active studies examining the potential of Targretin to serve as a Therapeutic procedure, treat Cutaneous Lymphoma, T-Cell and manage failure of at least one prior systemic therapy.
Condition
Clinical Trials
Trial Phases
Lymphoma, T-Cell, Cutaneous
0 Actively Recruiting
Disease
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Targretin Reviews: What are patients saying about Targretin?
5
Patient Review
2/21/2014
Targretin for Cutaneous T-Cell Lymphoma
4.7
Patient Review
1/17/2016
Targretin for Cutaneous T-Cell Lymphoma
4.3
Patient Review
8/17/2010
Targretin for Cutaneous T-Cell Lymphoma
3
Patient Review
2/3/2011
Targretin for Osteoporosis
2.7
Patient Review
7/31/2012
Targretin for Cutaneous T-Cell Lymphoma
2.3
Patient Review
2/5/2012
Targretin for Cutaneous T-Cell Lymphoma
Patient Q&A Section about targretin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Targretin a chemo drug?
"Bexarotene (Targretin®) is a chemotherapy regimen indicated for the treatment of patients with cutaneous manifestations of T-cell lymphoma who have not received prior systemic therapy."
Answered by AI
What does bexarotene treat?
"The drug Bexarotene, pronounced becks-a-roh-teen, is also known by its brand name Targretin, pronounced tar-gree-tin. It is a treatment for advanced skin lymphomas called cutaneous T cell lymphomas, which include mycosis fungoides and Sezary syndrome."
Answered by AI
What is Targretin used for?
"Targretin is used to treat the skin problems that come from a disease called cutaneous T-cell lymphoma. Your healthcare provider will need to supervise you while you use Targretin."
Answered by AI
How long does it take Targretin to work?
"Targretin can lower your white blood cell count. This is a common side effect that usually starts 4 to 8 weeks after starting the medication."
Answered by AI